PL3207035T3 - Compounds and compositions for modulating egfr mutant kinase activities - Google Patents

Compounds and compositions for modulating egfr mutant kinase activities

Info

Publication number
PL3207035T3
PL3207035T3 PL15850314T PL15850314T PL3207035T3 PL 3207035 T3 PL3207035 T3 PL 3207035T3 PL 15850314 T PL15850314 T PL 15850314T PL 15850314 T PL15850314 T PL 15850314T PL 3207035 T3 PL3207035 T3 PL 3207035T3
Authority
PL
Poland
Prior art keywords
compositions
compounds
kinase activities
egfr mutant
mutant kinase
Prior art date
Application number
PL15850314T
Other languages
Polish (pl)
Inventor
Byung-Chul Suh
Paresh Devidas Salgaonkar
Jaekyoo Lee
Jong Sung Koh
Ho-Juhn Song
In Yong Lee
Jaesang Lee
Dong Sik Jung
Jung-Ho Kim
Se-Won Kim
Original Assignee
Yuhan Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55654993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3207035(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yuhan Corporation filed Critical Yuhan Corporation
Publication of PL3207035T3 publication Critical patent/PL3207035T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL15850314T 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities PL3207035T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462063394P 2014-10-13 2014-10-13
EP15850314.4A EP3207035B1 (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities
PCT/KR2015/010784 WO2016060443A2 (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities

Publications (1)

Publication Number Publication Date
PL3207035T3 true PL3207035T3 (en) 2020-06-01

Family

ID=55654993

Family Applications (2)

Application Number Title Priority Date Filing Date
PL19196713T PL3604294T3 (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities
PL15850314T PL3207035T3 (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL19196713T PL3604294T3 (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities

Country Status (25)

Country Link
US (1) US9593098B2 (en)
EP (3) EP3604294B1 (en)
JP (3) JP6524221B2 (en)
KR (4) KR102208775B1 (en)
CN (2) CN106795144B (en)
AU (1) AU2015331166B2 (en)
BR (1) BR112017007769B1 (en)
CA (1) CA2962914C (en)
CY (2) CY1122737T1 (en)
DK (2) DK3604294T3 (en)
ES (2) ES2770058T3 (en)
HR (2) HRP20200201T1 (en)
HU (2) HUE048006T2 (en)
LT (2) LT3604294T (en)
MX (3) MX2017003181A (en)
NZ (1) NZ730012A (en)
PH (1) PH12017500488A1 (en)
PL (2) PL3604294T3 (en)
PT (2) PT3604294T (en)
RS (2) RS61865B1 (en)
RU (2) RU2727700C2 (en)
SG (1) SG11201701960XA (en)
SI (2) SI3604294T1 (en)
TW (2) TWI730331B (en)
WO (1) WO2016060443A2 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2962914C (en) * 2014-10-13 2018-10-23 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
WO2017044434A1 (en) 2015-09-11 2017-03-16 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
EP3399968B8 (en) 2016-01-07 2021-12-01 Xuanzhu Biopharmaceutical Co., Ltd. Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
MX2018013413A (en) * 2016-05-26 2019-06-06 Zeno Royalties & Milestones Llc Egfr inhibitor compounds.
KR102030886B1 (en) * 2016-09-23 2019-10-10 재단법인 대구경북첨단의료산업진흥재단 Novel imidazolyl pyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient
AR111469A1 (en) * 2017-04-21 2019-07-17 Yuhan Corp COME OUT OF AN AMINOPIRIDINE DERIVATIVE COMPOUND, A CRYSTAL FORM OF THE SAME, AND A PROCESS TO PREPARE THE SAME
MY199042A (en) * 2017-06-13 2023-10-11 Beijing Adamadle Biotechnology Llc Aminopyrimidine compound, preparation method therefor and use thereof
JP7189932B2 (en) * 2017-07-28 2022-12-14 ユハン コーポレーション Intermediates useful for the synthesis of selective inhibitors of protein kinases and processes for their preparation
CN111032650A (en) * 2017-07-28 2020-04-17 株式会社柳韩洋行 Novel intermediate useful for synthesis of aminopyrimidine derivative, method for preparing same, and method for preparing aminopyrimidine derivative using same
LT3658552T (en) * 2017-07-28 2023-11-27 Yuhan Corporation Process for preparing n-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamide by reacting the corresponding amine with a 3-halo-propionyl chloride
WO2019042187A1 (en) * 2017-08-30 2019-03-07 深圳市塔吉瑞生物医药有限公司 Aminopyrimidine compound and composition comprising same and use thereof
CN108047207A (en) * 2018-01-30 2018-05-18 天津大学 N- [5- (pyrimidine -2- amino) -2,4- di-substituted-phenyls] the deuterated objects of -2- fluoropropenes amides and application
CN108017633A (en) * 2018-01-30 2018-05-11 天津大学 N- [5- (pyrimidine -2- amino) -2,4- di-substituted-phenyls] -2- fluoropropenes amide derivatives and application
KR20200043618A (en) * 2018-10-18 2020-04-28 주식회사유한양행 Pharmaceutical composition for oral administration comprising an aminopyrimidine derivative or its salt
CN111349084B (en) * 2018-12-21 2022-11-25 深圳市塔吉瑞生物医药有限公司 Aminopyrimidines useful for inhibiting protein kinase activity
EP3931224A4 (en) 2019-02-26 2023-03-01 Janssen Biotech, Inc. Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
IL299831A (en) * 2019-03-19 2023-03-01 Voronoi Inc Heteroaryl derivative, method for producing the same, and pharmaceutical composition comprising same as effective component
CN111747931A (en) * 2019-03-29 2020-10-09 深圳福沃药业有限公司 Azaaromatic cyclic amide derivatives for the treatment of cancer
EP3946346A1 (en) 2019-03-29 2022-02-09 Astrazeneca AB Osimertinib for use in the treatment of non-small cell lung cancer
JOP20210304A1 (en) 2019-05-14 2023-01-30 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
US11850248B2 (en) * 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
CN110128354A (en) * 2019-06-20 2019-08-16 大连大学 A kind of preparation method of the fluoro- 2- mesyl -4- aminopyrimidine of 5-
KR20210032093A (en) 2019-09-16 2021-03-24 제이투에이치바이오텍 (주) Pyrimidine derivatives showing growth inhibition of EGFR mutation kinase and medical use thereof
WO2021094379A1 (en) 2019-11-12 2021-05-20 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CA3166980A1 (en) 2020-01-20 2021-07-29 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
TW202207940A (en) 2020-04-14 2022-03-01 美商健生生物科技公司 Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
KR20210152312A (en) * 2020-06-08 2021-12-15 주식회사 종근당 4-(4,5-dihydro-1h-pyrazol-1-yl)pyrimidine compound as cannabinoid receptor (cb1 receptor) antagonists and pharmaceutical composition including the same
EP4210702A1 (en) 2020-09-14 2023-07-19 JANSSEN Pharmaceutica NV Fgfr inhibitor combination therapies
TW202227425A (en) * 2020-09-18 2022-07-16 南韓商沃若諾伊生物公司 Heteroaryl derivatives, preparation method for the same, and a pharmaceutical composition comprising the same as an active ingredient
WO2022131741A1 (en) * 2020-12-14 2022-06-23 보로노이바이오 주식회사 Isoxazolidine derivative compound and use thereof
JP2024516721A (en) * 2021-05-07 2024-04-16 ボロノイ インコーポレイテッド Heteroaryl derivatives, methods for producing same, and pharmaceutical compositions containing same as active ingredient
EP4342895A1 (en) * 2021-05-17 2024-03-27 Voronoi Inc. Heteroaryl derivative compound and use thereof
WO2022253261A1 (en) 2021-06-01 2022-12-08 杭州领业医药科技有限公司 Hydrate crystal form of lazertinib methanesulfonate, preparation method therefor and use thereof
KR20230054567A (en) 2021-10-15 2023-04-25 제이투에이치바이오텍 (주) Compounds inhibiting ALK and/or EGFR mutation kinases and medical use thereof
TW202342057A (en) 2022-02-07 2023-11-01 美商健生生物科技公司 Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies
WO2023187037A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
WO2023209084A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209086A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds for treating cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2024002938A1 (en) 2022-06-27 2024-01-04 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
WO2024096624A1 (en) * 2022-11-03 2024-05-10 Voronoi Inc. Fumarate, tartrate, malate, and citrate salts of an egfr inhibitor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2400447C (en) * 2000-02-17 2008-04-22 Amgen Inc. Kinase inhibitors
CN1717396A (en) * 2002-11-28 2006-01-04 舍林股份公司 Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
JP4428565B2 (en) 2004-10-05 2010-03-10 東京エレクトロン株式会社 Treatment liquid application equipment
US20070072894A1 (en) 2005-03-24 2007-03-29 Kempf J V Synthesis of pyrroloquinoline quinone (PQQ)
JP5007029B2 (en) 2005-07-13 2012-08-22 Ｎｔｎ株式会社 Grease composition and rolling bearing with grease
BRPI0615270A2 (en) 2005-08-25 2009-08-04 Hoffmann La Roche fused pyrazole as p38 map kinase inhibitors
JP2007117465A (en) 2005-10-28 2007-05-17 Sharp Corp Dust collector and vacuum cleaner having the same
GB2450046B (en) 2006-03-29 2011-03-09 Kt Freetel Co Ltd Digital device and method for providing additional service by using the same
MX2008012482A (en) 2006-03-31 2008-10-10 Abbott Lab Indazole compounds.
ES2711249T3 (en) * 2008-06-27 2019-04-30 Celgene Car Llc Heteroaryl compounds and uses thereof
KR101705158B1 (en) * 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Egfr inhibitors and methods of treating diseases
EA024729B1 (en) * 2009-11-13 2016-10-31 Джиноско Kinase inhibitors
US9850227B2 (en) * 2011-02-25 2017-12-26 Yuhan Corporation Diaminopyrimidine derivatives and processes for the preparation thereof
EP4086246A1 (en) * 2011-07-27 2022-11-09 AstraZeneca AB 2-(2,4,5-substituted-anilino)pyrimidine compounds as egfr modulators
EP2804861B1 (en) * 2012-01-20 2018-02-28 Genosco Substituted pyrimidine compounds and their use as syk inhibitors
WO2014040555A1 (en) * 2012-09-12 2014-03-20 山东亨利医药科技有限责任公司 Nitrogen-containing heteroaromatic ring derivative as tyrosine kinase inhibitor
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
US10273224B2 (en) * 2013-08-22 2019-04-30 Jubilant Biosys Limited Substituted pyrimidine compounds, compositions and medicinal applications thereof
CN111892579B (en) * 2014-06-12 2023-07-25 上海艾力斯医药科技股份有限公司 Kinase inhibitors
CA2962914C (en) * 2014-10-13 2018-10-23 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
CN104788427B (en) * 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3 (2 pyrimdinyl-amino) phenylacryloyl amine compounds and its application

Also Published As

Publication number Publication date
HUE054848T2 (en) 2021-09-28
AU2015331166B2 (en) 2018-04-26
DK3207035T3 (en) 2020-01-27
BR112017007769A2 (en) 2018-01-16
WO2016060443A3 (en) 2016-06-23
JP2019163277A (en) 2019-09-26
EP3207035A2 (en) 2017-08-23
SI3207035T1 (en) 2020-04-30
PH12017500488A1 (en) 2017-07-31
KR20170066650A (en) 2017-06-14
NZ730012A (en) 2019-06-28
AU2015331166A1 (en) 2017-03-30
ES2770058T3 (en) 2020-06-30
TW201619150A (en) 2016-06-01
DK3604294T3 (en) 2021-06-28
CY1124359T1 (en) 2022-07-22
CN106795144A (en) 2017-05-31
BR112017007769B1 (en) 2023-10-10
EP3604294B1 (en) 2021-05-05
HUE048006T2 (en) 2020-05-28
SI3604294T1 (en) 2021-08-31
CA2962914C (en) 2018-10-23
JP2020196740A (en) 2020-12-10
RU2017116598A3 (en) 2018-11-21
JP6754864B2 (en) 2020-09-16
LT3207035T (en) 2020-02-25
CA2962914A1 (en) 2016-04-21
RU2020123547A (en) 2020-08-18
US9593098B2 (en) 2017-03-14
RU2017116598A (en) 2018-11-21
HRP20210949T1 (en) 2021-09-03
JP6524221B2 (en) 2019-06-05
KR102487451B1 (en) 2023-01-11
RS59900B1 (en) 2020-03-31
TWI730331B (en) 2021-06-11
KR102662358B1 (en) 2024-04-30
ES2879474T3 (en) 2021-11-22
SG11201701960XA (en) 2017-04-27
MX2020002168A (en) 2021-09-07
KR20230010836A (en) 2023-01-19
CN111686110A (en) 2020-09-22
KR102208775B1 (en) 2021-01-28
LT3604294T (en) 2021-07-26
MX2017003181A (en) 2017-07-20
JP2017530999A (en) 2017-10-19
PL3604294T3 (en) 2021-11-02
MX2021010761A (en) 2022-06-09
KR20200014944A (en) 2020-02-11
TW201938553A (en) 2019-10-01
WO2016060443A2 (en) 2016-04-21
PT3207035T (en) 2020-02-19
US20160102076A1 (en) 2016-04-14
HRP20200201T1 (en) 2020-05-15
EP3929190A1 (en) 2021-12-29
RU2727700C2 (en) 2020-07-23
EP3207035B1 (en) 2019-11-20
PT3604294T (en) 2021-07-29
TWI664173B (en) 2019-07-01
KR102073854B1 (en) 2020-02-05
EP3604294A1 (en) 2020-02-05
EP3207035A4 (en) 2018-03-14
CN111686110B (en) 2023-06-16
CN106795144B (en) 2020-06-16
CY1122737T1 (en) 2021-03-12
KR20210011068A (en) 2021-01-29
RS61865B1 (en) 2021-06-30

Similar Documents

Publication Publication Date Title
HRP20200201T1 (en) Compounds and compositions for modulating egfr mutant kinase activities
IL273058A (en) Compositions and methods for modulating pkk expression
HK1258811A1 (en) Compounds, compositions, and methods for modulating cftr
IL286669A (en) Compounds and methods for modulating tmprss6 expression
HK1258275A1 (en) Compounds and methods for modulating angiotensinogen expression
IL246879B (en) Apilimod compositions and methods for using same
ZA201700021B (en) Alk kinase inhibitor, and preparation method and use thereof
HRP20180920T1 (en) Mixed turf
EP3102571A4 (en) Substituted pyrimidines useful as egfr-t790m kinase inhibitors
PL3113774T3 (en) Compositions of grapiprant and methods for using the same
IL252191A0 (en) Compositions and methods for modulating at2r activity
SG10202003691PA (en) Composition for modulating irak1
GB201409661D0 (en) Novel compounds and their use as kinase inhibitors
GB201405532D0 (en) Novel compounds and their use as Kinase inhibitors